CD274 and triple-negative breast carcinoma: Using Raman mapping imaging, the nanoprobes were successfully used for in situ quantification and imaging of the PD-L1 expression on three different triple-negative breast cancer cell lines at the single-cell level, and for monitoring the PD-L1 expression variation during IFN-γ drug treatment.